1
|
Mandal S, Mallik S, Bhoumick A, Bhattacharya A, Sen P. Synthesis of Amino Acid-Based Cationic Lipids and Study of the Role of the Cationic Head Group for Enhanced Drug and Nucleic Acid Delivery. Chembiochem 2024; 25:e202300834. [PMID: 38284327 DOI: 10.1002/cbic.202300834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2023] [Revised: 01/17/2024] [Accepted: 01/26/2024] [Indexed: 01/30/2024]
Abstract
Leveraging liposomes for drug and nucleic acid delivery, though promising due to reduced toxicity and ease of preparation, faces challenges in stability and efficiency. To address this, we synthesized cationic amphiphiles from amino acids (arginine, lysine, and histidine). Histidine emerged as the superior candidate, leading to the development of three histidine-rich cationic amphiphiles for liposomes. Using the hydration method, we have prepared the liposomes and determined the optimal N/P ratios for lipoplex formation via gel electrophoresis. In vitro transfection assays compared the efficacy of our lipids to Fugene, while MTT assays gauged biocompatibility across cancer cell lines (MDA-MB 231 and MCF-7). The histidine-based lipid demonstrated marked potential in enhancing drug and nucleic acid delivery. This improvement stemmed from increased zeta potential, enhancing electrostatic interactions with nucleic acids and cellular uptake. Our findings underscore histidine's crucial role over lysine and arginine for effective delivery, revealing a significant correlation between histidine abundance and optimal performance. This study paves the way for histidine-enriched lipids as promising candidates for efficient drug and nucleic acid delivery, addressing key challenges in the field.
Collapse
Affiliation(s)
- Subhasis Mandal
- Indian Association for the Cultivation of Science, School of Biological Sciences, 2 A & 2B Raja S C Mullick Road, Kolkata, 700032
| | - Suman Mallik
- Indian Association for the Cultivation of Science, School of Biological Sciences, 2 A & 2B Raja S C Mullick Road, Kolkata, 700032
| | - Avinandan Bhoumick
- Indian Association for the Cultivation of Science, School of Biological Sciences, 2 A & 2B Raja S C Mullick Road, Kolkata, 700032
| | | | - Prosenjit Sen
- Indian Association for the Cultivation of Science, School of Biological Sciences, 2 A & 2B Raja S C Mullick Road, Kolkata, 700032
| |
Collapse
|
2
|
Oloo SO, Smith KM, Vicente MDGH. Multi-Functional Boron-Delivery Agents for Boron Neutron Capture Therapy of Cancers. Cancers (Basel) 2023; 15:3277. [PMID: 37444386 DOI: 10.3390/cancers15133277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 06/03/2023] [Accepted: 06/19/2023] [Indexed: 07/15/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary cancer treatment that involves the irradiation of 10B-containing tumors with low-energy neutrons (thermal or epithermal). The alpha particles and recoiling Li nuclei that are produced in the 10B-capture nuclear reaction are high-linear-energy transfer particles that destroy boron-loaded tumor cells; therefore, BNCT has the potential to be a localized therapeutic modality. Two boron-delivery agents have been used in clinical trials of BNCT in patients with malignant brain tumors, cutaneous melanoma, or recurrent tumors of the head and neck region, demonstrating the potential of BNCT in the treatment of difficult cancers. A variety of potentially highly effective boron-delivery agents have been synthesized in the past four decades and tested in cells and animal models. These include boron-containing nucleosides, peptides, proteins, polyamines, porphyrins, liposomes, monoclonal antibodies, and nanoparticles of various types. The most promising agents are multi-functional boronated molecules and nanoparticles functionalized with tumor cell-targeting moieties that increase their tumor selectivity and contain a radiolabel or fluorophore to allow quantification of 10B-biodistribution and treatment planning. This review discusses multi-functional boron agents reported in the last decade, but their full potential can only be ascertained after their evaluation in BNCT clinical trials.
Collapse
Affiliation(s)
- Sebastian O Oloo
- Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA
| | - Kevin M Smith
- Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA
| | | |
Collapse
|
3
|
Ailuno G, Balboni A, Caviglioli G, Lai F, Barbieri F, Dellacasagrande I, Florio T, Baldassari S. Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment. Cells 2022; 11:cells11244029. [PMID: 36552793 PMCID: PMC9776957 DOI: 10.3390/cells11244029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 12/09/2022] [Accepted: 12/11/2022] [Indexed: 12/15/2022] Open
Abstract
Boron neutron capture therapy is a low-invasive cancer therapy based on the neutron fission process that occurs upon thermal neutron irradiation of 10B-containing compounds; this process causes the release of alpha particles that selectively damage cancer cells. Although several clinical studies involving mercaptoundecahydro-closo-dodecaborate and the boronophenylalanine-fructose complex are currently ongoing, the success of this promising anticancer therapy is hampered by the lack of appropriate drug delivery systems to selectively carry therapeutic concentrations of boron atoms to cancer tissues, allowing prolonged boron retention therein and avoiding the damage of healthy tissues. To achieve these goals, numerous research groups have explored the possibility to formulate nanoparticulate systems for boron delivery. In this review. we report the newest developments on boron vehiculating drug delivery systems based on nanoparticles, distinguished on the basis of the type of carrier used, with a specific focus on the formulation aspects.
Collapse
Affiliation(s)
- Giorgia Ailuno
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
- Correspondence: (G.A.); (T.F.)
| | - Alice Balboni
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
| | | | - Francesco Lai
- Department of Life and Environmental Sciences (DiSVA), University of Cagliari, 09124 Cagliari, Italy
| | - Federica Barbieri
- Department of Internal Medicine, University of Genova, 16132 Genova, Italy
| | | | - Tullio Florio
- Department of Internal Medicine, University of Genova, 16132 Genova, Italy
- IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Correspondence: (G.A.); (T.F.)
| | - Sara Baldassari
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
| |
Collapse
|
4
|
Li F, Luo Z. Boron delivery agents for boron neutron capture therapy. CHINESE SCIENCE BULLETIN-CHINESE 2021. [DOI: 10.1360/tb-2021-1013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
5
|
Druzina AA, Zhidkova OB, Dudarova NV, Nekrasova NA, Suponitsky KY, Timofeev SV, Bregadze VI. Synthesis of Zwitter-Ionic Conjugate of Nido-Carborane with Cholesterol. Molecules 2021; 26:molecules26216687. [PMID: 34771096 PMCID: PMC8588508 DOI: 10.3390/molecules26216687] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 10/30/2021] [Accepted: 11/04/2021] [Indexed: 11/16/2022] Open
Abstract
9-HC≡CCH2Me2N-nido-7,8-C2B9H11, a previously described carboranyl terminal alkyne, was used for the copper(I)-catalyzed azide-alkyne cycloaddition with azido-3β-cholesterol to form a novel zwitter-ionic conjugate of nido-carborane with cholesterol, bearing a 1,2,3-triazol fragment. The conjugate of nido-carborane with cholesterol, containing a charge-compensated group in the linker, can be used as a precursor for the preparation of liposomes for BNCT (Boron Neutron Capture Therapy). The solid-state molecular structure of a nido-carborane derivative with the 9-Me2N(CH2)2Me2N-nido-7,8-C2B9H11 terminal dimethylamino group was determined by single-crystal X-ray diffraction.
Collapse
Affiliation(s)
- Anna A. Druzina
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119991 Moscow, Russia; (O.B.Z.); (N.V.D.); (N.A.N.); (K.Y.S.); (S.V.T.); (V.I.B.)
- Correspondence: ; Tel.: +7-926-404-5566
| | - Olga B. Zhidkova
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119991 Moscow, Russia; (O.B.Z.); (N.V.D.); (N.A.N.); (K.Y.S.); (S.V.T.); (V.I.B.)
| | - Nadezhda V. Dudarova
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119991 Moscow, Russia; (O.B.Z.); (N.V.D.); (N.A.N.); (K.Y.S.); (S.V.T.); (V.I.B.)
| | - Natalia A. Nekrasova
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119991 Moscow, Russia; (O.B.Z.); (N.V.D.); (N.A.N.); (K.Y.S.); (S.V.T.); (V.I.B.)
- M.V. Lomonosov Institute of Fine Chemical Technology, MIREA—Russian Technological University, 86 Vernadsky Av., 119571 Moscow, Russia
| | - Kyrill Yu. Suponitsky
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119991 Moscow, Russia; (O.B.Z.); (N.V.D.); (N.A.N.); (K.Y.S.); (S.V.T.); (V.I.B.)
- Basic Department of Chemistry of Innovative Materials and Technologies, G.V. Plekhanov Russian University of Economics, 36 Stremyannyi Line, 117997 Moscow, Russia
| | - Sergey V. Timofeev
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119991 Moscow, Russia; (O.B.Z.); (N.V.D.); (N.A.N.); (K.Y.S.); (S.V.T.); (V.I.B.)
| | - Vladimir I. Bregadze
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119991 Moscow, Russia; (O.B.Z.); (N.V.D.); (N.A.N.); (K.Y.S.); (S.V.T.); (V.I.B.)
| |
Collapse
|
6
|
Chiang CW, Chien YC, Yu WJ, Ho CY, Wang CY, Wang TW, Chiang CS, Keng PY. Polymer-Coated Nanoparticles for Therapeutic and Diagnostic Non- 10B Enriched Polymer-Coated Boron Carbon Oxynitride (BCNO) Nanoparticles as Potent BNCT Drug. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:2936. [PMID: 34835699 PMCID: PMC8618246 DOI: 10.3390/nano11112936] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Revised: 10/27/2021] [Accepted: 10/28/2021] [Indexed: 11/16/2022]
Abstract
Boron neutron capture therapy (BNCT) is a powerful and selective anti-cancer therapy utilizing 10B-enriched boron drugs. However, clinical advancement of BCNT is hampered by the insufficient loading of B-10 drugs throughout the solid tumor. Furthermore, the preparation of boron drugs for BNCT relies on the use of the costly B-10 enriched precursor. To overcome these challenges, polymer-coated boron carbon oxynitride (BCNO) nanoparticles, with ~30% of boron, were developed with enhanced biocompatibility, cell uptake, and tumoricidal effect via BNCT. Using the ALTS1C1 cancer cell line, the IC50 of the PEG@BCNO, bare, PEI@BCNO were determined to be 0.3 mg/mL, 0.1 mg/mL, and 0.05 mg/mL, respectively. As a proof-of-concept, the engineered non-10B enriched polymer-coated BCNO exhibited excellent anti-tumor effect via BNCT due to their high boron content per nanoparticle and due to the enhanced cellular internalization and retention compared to small molecular 10B-BPA drug. The astrocytoma ALTS1C1 cells treated with bare, polyethyleneimine-, and polyethylene glycol-coated BCNO exhibited an acute cell death of 24, 37, and 43%, respectively, upon 30 min of neutron irradiation compared to the negligible cell death in PBS-treated and non-irradiated cells. The radical approach proposed in this study addresses the expensive and complex issues of B-10 isotope enrichment process; thus, enabling the preparation of boron drugs at a significantly lower cost, which will facilitate the development of boron drugs for BNCT.
Collapse
Affiliation(s)
- Chen-Wei Chiang
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan; (C.-W.C.); (Y.-C.C.); (C.-Y.H.); (C.-Y.W.); (T.-W.W.)
| | - Yun-Chen Chien
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan; (C.-W.C.); (Y.-C.C.); (C.-Y.H.); (C.-Y.W.); (T.-W.W.)
| | - Wen-Jui Yu
- Department of Biomedical Engineering and Environmental Science, National Tsing Hua University, Hsinchu City 300, Taiwan; (W.-J.Y.); (C.-S.C.)
| | - Chia-Yu Ho
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan; (C.-W.C.); (Y.-C.C.); (C.-Y.H.); (C.-Y.W.); (T.-W.W.)
| | - Chih-Yi Wang
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan; (C.-W.C.); (Y.-C.C.); (C.-Y.H.); (C.-Y.W.); (T.-W.W.)
| | - Tzu-Wei Wang
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan; (C.-W.C.); (Y.-C.C.); (C.-Y.H.); (C.-Y.W.); (T.-W.W.)
| | - Chi-Shiun Chiang
- Department of Biomedical Engineering and Environmental Science, National Tsing Hua University, Hsinchu City 300, Taiwan; (W.-J.Y.); (C.-S.C.)
| | - Pei-Yuin Keng
- Department of Material Science and Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan; (C.-W.C.); (Y.-C.C.); (C.-Y.H.); (C.-Y.W.); (T.-W.W.)
| |
Collapse
|
7
|
Tsygankova AR, Gruzdev DA, Kanygin VV, Ya. Guselnikova T, Telegina AA, Kasatova AI, Kichigin AI, Levit GL, Mechetina LV, Mukhamadiyarov RA, Razumov IA, Solovieva OI, Yu. Volkova O, Ponomarev AA, Krasnov VP, Zavjalov EL. Liposomes loaded with lipophilic derivative of closo-carborane as a potential boron delivery system for boron neutron capture therapy of tumors. MENDELEEV COMMUNICATIONS 2021. [DOI: 10.1016/j.mencom.2021.09.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Zhang W, Wang K, Hu X, Zhang X, Chang S, Zhang H. Nanometer-Sized Boron Loaded Liposomes Containing Fe 3O 4 Magnetic Nanoparticles and Tributyl Borate and Anti-Albumin from Bovine Serum Antibody for Thermal Neutron Detection. MATERIALS 2021; 14:ma14113040. [PMID: 34204954 PMCID: PMC8199906 DOI: 10.3390/ma14113040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/24/2021] [Revised: 05/22/2021] [Accepted: 05/29/2021] [Indexed: 11/27/2022]
Abstract
A shortage in the supply of 3He used for thermal neutron detector makes researchers to find 3He alternatives for developing new neutron detectors. Here, we prepared a neutron-sensitive composite liposome with tributyl borate and encapsulating with Fe3O4@oleic acid nanoparticles (Fe3O4@OA NPs), methylene blue (MB), or anti-albumin from bovine serum (anti-BSA). The tributyl borate compound was characterized by Fourier transform infrared spectroscopy (FT-IR). In addition, the morphology, element compositions, and magnetic properties of the composite liposome were investigated with transmission electron microscopy (TEM), energy-dispersive X-ray spectroscopy (EDS), and vibrating sample magnetometer (VSM), respectively. The results indicated that a typical ellipsoidal magnetic liposome structure was obtained, and the lengths of the minor axis and major axis were 49 ± 1 nm and 87 ± 3 nm, respectively. Under thermal neutron irradiation, the structure of composite liposome was destroyed, and encapsulated reporter molecules were released, which was detected by ultraviolet–visible (UV–vis) spectroscopy and surface plasmon resonance (SPR) technology. The response of this sensor based on a destructive assay shows a good correlation with neutron doses. Besides, the sensor has a neutron to gamma-ray rejection ratio of 1568 at a thermal neutron flux rate of 135.6 n/cm2·s, which makes it a promising alternative to 3He.
Collapse
Affiliation(s)
- Wei Zhang
- College of Materials Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing 211100, China; (W.Z.); (K.W.); (X.H.); (X.Z.)
| | - Kaikai Wang
- College of Materials Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing 211100, China; (W.Z.); (K.W.); (X.H.); (X.Z.)
| | - Xiaodan Hu
- College of Materials Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing 211100, China; (W.Z.); (K.W.); (X.H.); (X.Z.)
| | - Xiaohong Zhang
- College of Materials Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing 211100, China; (W.Z.); (K.W.); (X.H.); (X.Z.)
| | - Shuquan Chang
- College of Materials Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing 211100, China; (W.Z.); (K.W.); (X.H.); (X.Z.)
- Correspondence: (S.C.); (H.Z.)
| | - Haiqian Zhang
- College of Materials Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing 211100, China; (W.Z.); (K.W.); (X.H.); (X.Z.)
- Jiangsu Key Laboratory for Biomaterials and Devices, Southeast University, Nanjing 210096, China
- Correspondence: (S.C.); (H.Z.)
| |
Collapse
|
9
|
Murphy N, McCarthy E, Dwyer R, Farràs P. Boron clusters as breast cancer therapeutics. J Inorg Biochem 2021; 218:111412. [PMID: 33773323 DOI: 10.1016/j.jinorgbio.2021.111412] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 02/21/2021] [Accepted: 02/24/2021] [Indexed: 12/16/2022]
Abstract
Since the foundation of small molecule-based therapeutics over 100 years ago, their design has been dominated by organic based components. This has also been apparent in anti-cancer therapeutics in a broad range of strategies; from the older DNA chelating drugs, to the more recent molecular-targeted therapies. The main challenges facing current treatments; multidrug resistance and low therapeutic index, can potentially be alleviated by the incorporation of boron clusters. While retaining the versatility of their organic counterparts, these compounds offer a unique set of molecular interactions, which are a useful tool in targeted therapies and can improve many organic formulations with their incorporation. This review will discuss the potential of boron clusters in medicine while focusing on their activity in the breast cancer setting.
Collapse
Affiliation(s)
- Neville Murphy
- School of Chemistry, Ryan Institute, National University of Ireland, Galway H91CF50, Ireland; CÚRAM, the SFI Research Centre for Medical Devices, National University of Ireland, Galway H91W2TY, Ireland
| | - Elan McCarthy
- Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland
| | - Róisín Dwyer
- Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland; CÚRAM, the SFI Research Centre for Medical Devices, National University of Ireland, Galway H91W2TY, Ireland
| | - Pau Farràs
- School of Chemistry, Ryan Institute, National University of Ireland, Galway H91CF50, Ireland; CÚRAM, the SFI Research Centre for Medical Devices, National University of Ireland, Galway H91W2TY, Ireland.
| |
Collapse
|
10
|
Immobilization of carboranes on Fe3O4-polymer nanocomposites for potential application in boron neutron cancer therapy. Colloids Surf A Physicochem Eng Asp 2020. [DOI: 10.1016/j.colsurfa.2020.125035] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
11
|
Boron neutron capture therapy for malignant brain tumors. J Neurooncol 2020; 149:1-11. [DOI: 10.1007/s11060-020-03586-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Accepted: 07/11/2020] [Indexed: 01/12/2023]
|
12
|
|
13
|
Lee W, Sarkar S, Ahn H, Kim JY, Lee YJ, Chang Y, Yoo J. PEGylated liposome encapsulating nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT). Biochem Biophys Res Commun 2019; 522:669-675. [PMID: 31787237 DOI: 10.1016/j.bbrc.2019.11.144] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Accepted: 11/21/2019] [Indexed: 11/19/2022]
Abstract
Boron neutron capture therapy (BNCT) is a binary radiotherapy based on nuclear reactions that occur when boron-10 is irradiated with neutrons, which result in the ejection of high-energy alpha particles. Successful BNCT requires the efficient delivery of a boron-containing compound to effect high concentrations in tumor cells while minimizing uptake in normal tissues. In this study, PEGylated liposomes were employed as boron carriers to maximize delivery to tumors and minimize uptake in the reticuloendothelial system (RES). The water-soluble potassium salt of nido-7,8-carborane, nido-carborane, was chosen as the boron source due to its high boron content per molecule. Nido-carborane was encapsulated in the aqueous cores of PEGylated liposomes by hydrating thin lipid films. Repeated freezing and thawing increased nido-carborane loading by up to 47.5 ± 3.1%. The average hydrodynamic diameter of the prepared boronated liposomes was determined to be 114.5 ± 28 nm through dynamic light scattering (DLS) measurement. Globular liposomes approximately 100 nm in diameter were clearly visible in transmission electron microscope (TEM) images. The viability of tumor cells following BNCT with 70 μM nido-carborane was reduced to 17.1% compared to irradiated control cells, which did not contain boronated liposomes. Confocal microscopy revealed that fluorescently labeled liposomes injected into the tail veins of mice were deeply and evenly distributed in tumor tissues and localized in the cytoplasm of tumor cells. When mice were properly shielded with a 12 mm-thick polyethylene board during in-vivo irradiation at a thermal neutron flux of 1.94 × 104/cm2·sec, almost complete tumor suppression was achieved in tumor models injected with boronated liposomes (21.0 mg 10B/kg). Two BNCT cycles spaced 10 days apart further enhanced the therapeutic anti-tumor effect, even when the dose was lowered to 10.5 mg 10B/kg. No notable weight loss was observed in the tumor models during the BNCT study.
Collapse
Affiliation(s)
- Woonghee Lee
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea
| | - Swarbhanu Sarkar
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea
| | - Heesu Ahn
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea
| | - Jung Young Kim
- Division of Applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, 01812, Republic of Korea
| | - Yong Jin Lee
- Division of Applied RI, Korea Institute of Radiological and Medical Sciences, Seoul, 01812, Republic of Korea
| | - Yongmin Chang
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea
| | - Jeongsoo Yoo
- Department of Molecular Medicine, BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
| |
Collapse
|
14
|
Dukenbayev K, Korolkov IV, Tishkevich DI, Kozlovskiy AL, Trukhanov SV, Gorin YG, Shumskaya EE, Kaniukov EY, Vinnik DA, Zdorovets MV, Anisovich M, Trukhanov AV, Tosi D, Molardi C. Fe₃O₄ Nanoparticles for Complex Targeted Delivery and Boron Neutron Capture Therapy. NANOMATERIALS 2019; 9:nano9040494. [PMID: 30935156 PMCID: PMC6523109 DOI: 10.3390/nano9040494] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/17/2019] [Revised: 03/17/2019] [Accepted: 03/22/2019] [Indexed: 01/11/2023]
Abstract
Magnetic Fe3O4 nanoparticles (NPs) and their surface modification with therapeutic substances are of great interest, especially drug delivery for cancer therapy, including boron-neutron capture therapy (BNCT). In this paper, we present the results of boron-rich compound (carborane borate) attachment to previously aminated by (3-aminopropyl)-trimethoxysilane (APTMS) iron oxide NPs. Fourier transform infrared spectroscopy with Attenuated total reflectance accessory (ATR-FTIR) and energy-dispersive X-ray analysis confirmed the change of the element content of NPs after modification and formation of new bonds between Fe3O4 NPs and the attached molecules. Transmission (TEM) and scanning electron microscopy (SEM) showed Fe3O4 NPs’ average size of 18.9 nm. Phase parameters were studied by powder X-ray diffraction (XRD), and the magnetic behavior of Fe3O4 NPs was elucidated by Mössbauer spectroscopy. The colloidal and chemical stability of NPs was studied using simulated body fluid (phosphate buffer—PBS). Modified NPs have shown excellent stability in PBS (pH = 7.4), characterized by XRD, Mössbauer spectroscopy, and dynamic light scattering (DLS). Biocompatibility was evaluated in-vitro using cultured mouse embryonic fibroblasts (MEFs). The results show us an increasing of IC50 from 0.110 mg/mL for Fe3O4 NPs to 0.405 mg/mL for Fe3O4-Carborane NPs. The obtained data confirm the biocompatibility and stability of synthesized NPs and the potential to use them in BNCT.
Collapse
Affiliation(s)
- Kanat Dukenbayev
- School of Engineering, Nazarbayev University, 010000 Nur-Sultan, Kazakhstan.
| | - Ilya V Korolkov
- The Institute of Nuclear Physics, 050032 Almaty, Kazakhstan.
- L.N. Gumilyov Eurasian National University, 010008 Nur-Sultan, Kazakhstan.
| | - Daria I Tishkevich
- Laboratory of Magnetic Films Physics, Cryogenic Research Department, Scientific-Practical Materials Research Centre, National Academy of Sciences of Belarus, 220072 Minsk, Belarus.
- Laboratory of Single crystal growth, South Ural State University, 454080 Chelyabinsk, Russia.
| | - Artem L Kozlovskiy
- The Institute of Nuclear Physics, 050032 Almaty, Kazakhstan.
- L.N. Gumilyov Eurasian National University, 010008 Nur-Sultan, Kazakhstan.
| | - Sergey V Trukhanov
- Laboratory of Magnetic Films Physics, Cryogenic Research Department, Scientific-Practical Materials Research Centre, National Academy of Sciences of Belarus, 220072 Minsk, Belarus.
- Laboratory of Single crystal growth, South Ural State University, 454080 Chelyabinsk, Russia.
| | - Yevgeniy G Gorin
- The Institute of Nuclear Physics, 050032 Almaty, Kazakhstan.
- L.N. Gumilyov Eurasian National University, 010008 Nur-Sultan, Kazakhstan.
| | - Elena E Shumskaya
- Laboratory of Magnetic Films Physics, Cryogenic Research Department, Scientific-Practical Materials Research Centre, National Academy of Sciences of Belarus, 220072 Minsk, Belarus.
| | - Egor Y Kaniukov
- Laboratory of Magnetic Films Physics, Cryogenic Research Department, Scientific-Practical Materials Research Centre, National Academy of Sciences of Belarus, 220072 Minsk, Belarus.
- Laboratory of Single crystal growth, South Ural State University, 454080 Chelyabinsk, Russia.
- Department of Electronic Materials Technology, National University of Science and Technology MISiS, 119049 Moscow, Russia.
| | - Denis A Vinnik
- Laboratory of Single crystal growth, South Ural State University, 454080 Chelyabinsk, Russia.
| | - Maxim V Zdorovets
- The Institute of Nuclear Physics, 050032 Almaty, Kazakhstan.
- L.N. Gumilyov Eurasian National University, 010008 Nur-Sultan, Kazakhstan.
- Ural Federal University named after the First President of Russia B.N. Yeltsin, 620075 Yekaterinburg, Russia.
| | - Marina Anisovich
- Republican Unitary Enterprise "Scientific-Practical Centre of Hygiene", 220012 Minsk, Belarus.
| | - Alex V Trukhanov
- Laboratory of Magnetic Films Physics, Cryogenic Research Department, Scientific-Practical Materials Research Centre, National Academy of Sciences of Belarus, 220072 Minsk, Belarus.
- Laboratory of Single crystal growth, South Ural State University, 454080 Chelyabinsk, Russia.
- Department of Electronic Materials Technology, National University of Science and Technology MISiS, 119049 Moscow, Russia.
| | - Daniele Tosi
- School of Engineering, Nazarbayev University, 010000 Nur-Sultan, Kazakhstan.
| | - Carlo Molardi
- School of Engineering, Nazarbayev University, 010000 Nur-Sultan, Kazakhstan.
| |
Collapse
|
15
|
Nar I, Bortolussi S, Postuma I, Atsay A, Berksun E, Viola E, Ferrari C, Cansolino L, Ricciardi G, Donzello MP, Hamuryudan E. A Phthalocyanine‐
ortho
‐Carborane Conjugate for Boron Neutron Capture Therapy: Synthesis, Physicochemical Properties, and in vitro Tests. Chempluschem 2019; 84:345-351. [DOI: 10.1002/cplu.201800560] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 12/14/2018] [Indexed: 12/25/2022]
Affiliation(s)
- Ilgın Nar
- Department of ChemistryIstanbul Technical University 34469, Maslak Istanbul Turkey
| | - Silva Bortolussi
- Dipartimento di FisicaUniversità of Pavia Via Bassi 6 27100 Pavia Italy
- Istituto Nazionale Di Fisica Nucleare (INFN)Unit of Pavia Italy
| | - Ian Postuma
- Dipartimento di FisicaUniversità of Pavia Via Bassi 6 27100 Pavia Italy
| | - Armağan Atsay
- Department of ChemistryIstanbul Technical University 34469, Maslak Istanbul Turkey
| | - Ekin Berksun
- Department of ChemistryIstanbul Technical University 34469, Maslak Istanbul Turkey
| | - Elisa Viola
- Dipartimento di ChimicaUniversità di Roma Sapienza Piazzale A. Moro 5 I-00185 Roma Italy
| | - Cinzia Ferrari
- Dipartimento di Scienze Clinico-ChirurgicheLaboratorio di Chirurgia SperimentaleUniversità di Pavia Via Ferrata 9 27100 Pavia Italy
| | - Laura Cansolino
- Dipartimento di Scienze Clinico-ChirurgicheLaboratorio di Chirurgia SperimentaleUniversità di Pavia Via Ferrata 9 27100 Pavia Italy
| | - Giampaolo Ricciardi
- Scuola di Scienze Agrarie, Alimentari, Forestali e Ambientali (SAFE)Università della Basilicata Viale dell'Ateneo Lucano 10 85100 Potenza Italy
| | - Maria Pia Donzello
- Dipartimento di ChimicaUniversità di Roma Sapienza Piazzale A. Moro 5 I-00185 Roma Italy
| | - Esin Hamuryudan
- Department of ChemistryIstanbul Technical University 34469, Maslak Istanbul Turkey
| |
Collapse
|
16
|
Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond) 2018; 38:35. [PMID: 29914561 PMCID: PMC6006782 DOI: 10.1186/s40880-018-0299-7] [Citation(s) in RCA: 220] [Impact Index Per Article: 36.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Accepted: 05/08/2018] [Indexed: 02/07/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary radiotherapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope, boron-10, is irradiated with neutrons to produce high energy alpha particles. This review will focus on tumor-targeting boron delivery agents that are an essential component of this binary system. Two low molecular weight boron-containing drugs currently are being used clinically, boronophenylalanine (BPA) and sodium borocaptate (BSH). Although they are far from being ideal, their therapeutic efficacy has been demonstrated in patients with high grade gliomas, recurrent tumors of the head and neck region, and a much smaller number with cutaneous and extra-cutaneous melanomas. Because of their limitations, great effort has been expended over the past 40 years to develop new boron delivery agents that have more favorable biodistribution and uptake for clinical use. These include boron-containing porphyrins, amino acids, polyamines, nucleosides, peptides, monoclonal antibodies, liposomes, nanoparticles of various types, boron cluster compounds and co-polymers. Currently, however, none of these have reached the stage where there is enough convincing data to warrant clinical biodistribution studies. Therefore, at present the best way to further improve the clinical efficacy of BNCT would be to optimize the dosing paradigms and delivery of BPA and BSH, either alone or in combination, with the hope that future research will identify new and better boron delivery agents for clinical use.
Collapse
Affiliation(s)
- Rolf F. Barth
- Department of Pathology, The Ohio State University, 4132 Graves Hall, 333 W. 10th Ave, Columbus, OH 43210 USA
| | - Peng Mi
- Department of Radiology, Center for Medical Imaging, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan 610041 P. R. China
| | - Weilian Yang
- Department of Pathology, The Ohio State University, 4132 Graves Hall, 333 W. 10th Ave, Columbus, OH 43210 USA
- Present Address: Neurosurgery and Brain and Nerve Research Laboratory, The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu 215004 P. R. China
| |
Collapse
|
17
|
Piskorz J, Mlynarczyk DT, Szczolko W, Konopka K, Düzgüneş N, Mielcarek J. Liposomal formulations of magnesium sulfanyl tribenzoporphyrazines for the photodynamic therapy of cancer. J Inorg Biochem 2018; 184:34-41. [PMID: 29679798 DOI: 10.1016/j.jinorgbio.2018.04.010] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Revised: 03/22/2018] [Accepted: 04/08/2018] [Indexed: 12/12/2022]
Abstract
Photodynamic therapy of cancer comprises the activation of photosensitizer molecules delivered to cancer cells, to generate reactive oxygen species that mediate cytotoxicity. In this study, previously synthesized dendritic magnesium tribenzoporphyrazines were incorporated into four types of liposomes containing either 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as the zwitterionic lipids. The addition of either l-α-phosphatidyl-dl-glycerol (PG) or 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) imparted a negative or positive charge, respectively. Novel formulations were tested in oral squamous cell carcinoma cell lines (CAL 27, HSC-3) as well as cervical adenocarcinoma cells (HeLa). Positively charged DOTAP:POPC liposomes were the most effective carriers for all tested tribenzoporphyrazines. Calculated IC50 values for DOTAP:POPC liposomes indicated that the incorporation of tribenzoporphyrazines into these liposomes can improve photocytotoxicity up to 50-fold compared to the free forms of macrocycles. Oral cancer cells (CAL 27 and HSC-3) were more sensitive to liposomal photodynamic treatment than HeLa cells.
Collapse
Affiliation(s)
- Jaroslaw Piskorz
- Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznan, Poland.
| | - Dariusz T Mlynarczyk
- Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznan, Poland
| | - Wojciech Szczolko
- Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznan, Poland
| | - Krystyna Konopka
- Department of Biomedical Sciences, University of the Pacific, 155 Fifth Street, San Francisco, CA 94103, USA
| | - Nejat Düzgüneş
- Department of Biomedical Sciences, University of the Pacific, 155 Fifth Street, San Francisco, CA 94103, USA
| | - Jadwiga Mielcarek
- Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznan, Poland
| |
Collapse
|
18
|
Ay AN, Akar H, Zaulet A, Viňas C, Teixidor F, Zumreoglu-Karan B. Carborane-layered double hydroxide nanohybrids for potential targeted- and magnetically targeted-BNCT applications. Dalton Trans 2017; 46:3303-3310. [DOI: 10.1039/c7dt00100b] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Carborane-intercalated layered double hydroxide nanohybrids (CB-LDH) and a magnesium ferrite (MF) supported-CB-LDH core–shell nanocomposite (CB-LDH@MF) are reported.
Collapse
Affiliation(s)
- Ahmet Nedim Ay
- Department of Chemistry
- Hacettepe University
- 06800 Ankara
- Turkey
| | - Hande Akar
- Department of Chemistry
- Hacettepe University
- 06800 Ankara
- Turkey
| | - Adnana Zaulet
- Institut de Ciència de MaterialsdeBarcelona(ICMAB-CSIC)
- 08193 Bellaterra
- Spain
| | - Clara Viňas
- Institut de Ciència de MaterialsdeBarcelona(ICMAB-CSIC)
- 08193 Bellaterra
- Spain
| | - Francesc Teixidor
- Institut de Ciència de MaterialsdeBarcelona(ICMAB-CSIC)
- 08193 Bellaterra
- Spain
| | | |
Collapse
|
19
|
MIYATAKE SI, KAWABATA S, HIRAMATSU R, KUROIWA T, SUZUKI M, KONDO N, ONO K. Boron Neutron Capture Therapy for Malignant Brain Tumors. Neurol Med Chir (Tokyo) 2016; 56:361-71. [PMID: 27250576 PMCID: PMC4945594 DOI: 10.2176/nmc.ra.2015-0297] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2015] [Accepted: 02/27/2016] [Indexed: 01/17/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Therefore, BNCT enables the application of a high dose of particle radiation selectively to tumor cells in which boron-10 compound has been accumulated. We applied BNCT using nuclear reactors for 167 cases of malignant brain tumors, including recurrent malignant gliomas, newly diagnosed malignant gliomas, and recurrent high-grade meningiomas from January 2002 to May 2014. Here, we review the principle and history of BNCT. In addition, we introduce fluoride-18-labeled boronophenylalanine positron emission tomography and the clinical results of BNCT for the above-mentioned malignant brain tumors. Finally, we discuss the recent development of accelerators producing epithermal neutron beams. This development could provide an alternative to the current use of specially modified nuclear reactors as a neutron source, and could allow BNCT to be performed in a hospital setting.
Collapse
Affiliation(s)
- Shin-Ichi MIYATAKE
- Cancer Center, Osaka Medical College, Takatsuki, Osaka
- Department of Neurosurgery, Osaka Medical College, Takatsuki, Osaka
| | - Shinji KAWABATA
- Department of Neurosurgery, Osaka Medical College, Takatsuki, Osaka
| | - Ryo HIRAMATSU
- Department of Neurosurgery, Osaka Medical College, Takatsuki, Osaka
| | | | - Minoru SUZUKI
- Particle Radiation Oncology Research Center, Kyoto University Research, Reactor Institute, Kumatori, Osaka
| | - Natsuko KONDO
- Particle Radiation Oncology Research Center, Kyoto University Research, Reactor Institute, Kumatori, Osaka
| | - Koji ONO
- Particle Radiation Oncology Research Center, Kyoto University Research, Reactor Institute, Kumatori, Osaka
| |
Collapse
|
20
|
Portu A, Postuma I, Gadan MA, Saint Martin G, Olivera MS, Altieri S, Protti N, Bortolussi S. Reprint of Inter-comparison of boron concentration measurements at INFN-University of Pavia (Italy) and CNEA (Argentina). Appl Radiat Isot 2015; 106:171-5. [DOI: 10.1016/j.apradiso.2015.10.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2015] [Revised: 04/29/2015] [Accepted: 07/22/2015] [Indexed: 11/28/2022]
|
21
|
Inter-comparison of boron concentration measurements at INFN-University of Pavia (Italy) and CNEA (Argentina). Appl Radiat Isot 2015; 105:35-39. [PMID: 26454177 DOI: 10.1016/j.apradiso.2015.07.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2015] [Revised: 04/29/2015] [Accepted: 07/22/2015] [Indexed: 11/20/2022]
Abstract
An inter-comparison of three boron determination techniques was carried out between laboratories from INFN-University of Pavia (Italy) and CNEA (Argentina): alpha spectrometry (alpha-spect), neutron capture radiography (NCR) and quantitative autoradiography (QTA). Samples of different nature were analysed: liquid standards, liver homogenates and tissue samples from different treatment protocols. The techniques showed a good agreement in a concentration range of interest in BNCT (1-100ppm), thus demonstrating their applicability as precise methods to quantify boron and determine its distribution in tissues.
Collapse
|
22
|
Luderer MJ, de la Puente P, Azab AK. Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy. Pharm Res 2015; 32:2824-36. [DOI: 10.1007/s11095-015-1718-y] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Accepted: 05/18/2015] [Indexed: 01/16/2023]
|
23
|
Zhao Y, Zhang S, Zhang Y, Cui S, Chen H, Zhi D, Zhen Y, Zhang S, Huang L. Tri-peptide cationic lipids for gene delivery. J Mater Chem B 2015; 3:119-126. [PMID: 25580248 PMCID: PMC4285367 DOI: 10.1039/c4tb01312c] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Several novel tri-peptide cationic lipids were designed and synthesized for delivering DNA and siRNA. They have tri-lysine and tri-ornithine as head groups, carbamate group as linker and 12 and 14 carbon atom alkyl groups as tails. These tri-peptide cationic lipids were prepared into cationic liposomes for the study of the physicochemical properties and gene delivery. Their particle size, Zeta potential and DNA-binding were characterized to show that they were suitable for gene transfection. The further results indicate that these lipids can transfer DNA and siRNA very efficiently into NCI-H460 and Hep-2 tumor cells. The selected lipid, CDO14, was able to deliver combined siRNAs against c-Myc and VEGF for silencing distinct oncogenic pathways in lung tumors of mice, with little in vitro and in vivo toxicity.
Collapse
Affiliation(s)
- Yinan Zhao
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116021, Liaoning, China
- SEAC-ME Key Laboratory of Biotechnology and Bio-resources Utilization, Dalian Nationalities University, Dalian 116600, Liaoning, China
| | - Shubiao Zhang
- SEAC-ME Key Laboratory of Biotechnology and Bio-resources Utilization, Dalian Nationalities University, Dalian 116600, Liaoning, China
| | - Yuan Zhang
- Department of Materials Science and Engineering, Department of Biological Engineering, The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Shaohui Cui
- SEAC-ME Key Laboratory of Biotechnology and Bio-resources Utilization, Dalian Nationalities University, Dalian 116600, Liaoning, China
| | - Huiying Chen
- SEAC-ME Key Laboratory of Biotechnology and Bio-resources Utilization, Dalian Nationalities University, Dalian 116600, Liaoning, China
| | - Defu Zhi
- SEAC-ME Key Laboratory of Biotechnology and Bio-resources Utilization, Dalian Nationalities University, Dalian 116600, Liaoning, China
| | - Yuhong Zhen
- College of Phamacy, Dalian Medical University, Dalian 116044, Liaoning, China
| | - Shufen Zhang
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116021, Liaoning, China
| | - Leaf Huang
- Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| |
Collapse
|
24
|
Pietrangeli D, Rosa A, Pepe A, Altieri S, Bortolussi S, Postuma I, Protti N, Ferrari C, Cansolino L, Clerici AM, Viola E, Donzello MP, Ricciardi G. Water-soluble carboranyl-phthalocyanines for BNCT. Synthesis, characterization, and in vitro tests of the Zn(ii)-nido-carboranyl-hexylthiophthalocyanine. Dalton Trans 2015; 44:11021-8. [DOI: 10.1039/c5dt00394f] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Nido-[ZnMCHESPc]Cs8 increases boron concentration in selected cancerous cell lines.
Collapse
|
25
|
Alberti D, Toppino A, Geninatti Crich S, Meraldi C, Prandi C, Protti N, Bortolussi S, Altieri S, Aime S, Deagostino A. Synthesis of a carborane-containing cholesterol derivative and evaluation as a potential dual agent for MRI/BNCT applications. Org Biomol Chem 2014; 12:2457-67. [PMID: 24604345 DOI: 10.1039/c3ob42414f] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
In this study the synthesis and characterization of a new dual, imaging and therapeutic, agent is proposed with the aim of improving the efficacy of Boron Neutron Capture Therapy (BNCT) in cancer treatment. The agent (Gd-B-AC01) consists of a carborane unit (ten boron atoms) bearing a cholesterol unit on one side (to pursue the incorporation into the liposome bi-layer) and a Gd(iii)/1,4,7,10-tetraazacyclododecane monoamide complex on the other side (as a MRI reporter to attain the quantification of the B/Gd concentration). In order to endow the BNCT agent with specific delivery properties, the liposome embedded with the MRI/BNCT dual probes has been functionalized with a pegylated phospholipid containing a folic acid residue at the end of the PEG chain. The vector allows the binding of the liposome to folate receptors that are overexpressed in many tumor types, and in particular, in human ovarian cancer cells (IGROV-1). An in vitro test on IGROV-1 cells demonstrated that Gd-B-AC01 loaded liposomes are efficient carriers for the delivery of the MRI/BNCT probes to the tumor cells. Finally, the BNCT treatment of IGROV-1 cells showed that the number of surviving cells was markedly smaller when the cells were irradiated after internalization of the folate-targeted GdB10-AC01/liposomes.
Collapse
Affiliation(s)
- Diego Alberti
- Department of Molecular Biotechnology and Health Sciences, University of Torino, via Nizza 52, 10126, Torino, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes for oral cancer in the hamster cheek pouch model. Proc Natl Acad Sci U S A 2014; 111:16077-81. [PMID: 25349432 DOI: 10.1073/pnas.1410865111] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The application of boron neutron capture therapy (BNCT) mediated by liposomes containing (10)B-enriched polyhedral borane and carborane derivatives for the treatment of head and neck cancer in the hamster cheek pouch oral cancer model is presented. These liposomes are composed of an equimolar ratio of cholesterol and 1,2-distearoyl-sn-glycero-3-phosphocholine, incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] (MAC) in the bilayer membrane while encapsulating the hydrophilic species Na3[ae-B20H17NH3] (TAC) in the aqueous core. Unilamellar liposomes with a mean diameter of 83 nm were administered i.v. in hamsters. After 48 h, the boron concentration in tumors was 67 ± 16 ppm whereas the precancerous tissue contained 11 ± 6 ppm, and the tumor/normal pouch tissue boron concentration ratio was 10:1. Neutron irradiation giving a 5-Gy dose to precancerous tissue (corresponding to 21 Gy in tumor) resulted in an overall tumor response (OR) of 70% after a 4-wk posttreatment period. In contrast, the beam-only protocol gave an OR rate of only 28%. Once-repeated BNCT treatment with readministration of liposomes at an interval of 4, 6, or 8 wk resulted in OR rates of 70-88%, of which the complete response ranged from 37% to 52%. Because of the good therapeutic outcome, it was possible to extend the follow-up of BNCT treatment groups to 16 wk after the first treatment. No radiotoxicity to normal tissue was observed. A salient advantage of these liposomes was that only mild mucositis was observed in dose-limiting precancerous tissue with a sustained tumor response of 70-88%.
Collapse
|
27
|
Blood–brain barrier (BBB) toxicity and permeability assessment after L-(4-10Boronophenyl)alanine, a conventional B-containing drug for boron neutron capture therapy, using an in vitro BBB model. Brain Res 2014; 1583:34-44. [DOI: 10.1016/j.brainres.2014.08.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Accepted: 08/07/2014] [Indexed: 12/24/2022]
|
28
|
Kanazawa J, Takita R, Uchiyama M. The Development of C-C Cross-Coupling Reaction of Monocarba-<i>closo</i>-dodecaborate Anion for the Synthesis of Functional Molecules. YAKUGAKU ZASSHI 2014; 134:783-8. [DOI: 10.1248/yakushi.14-00017-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
| | - Ryo Takita
- Graduate School of Pharmaceutical Sciences, The University of Tokyo
- Elements Chemistry Laboratory, RIKEN
| | - Masanobu Uchiyama
- Graduate School of Pharmaceutical Sciences, The University of Tokyo
- Elements Chemistry Laboratory, RIKEN
| |
Collapse
|
29
|
Bortolussi S, Ciani L, Postuma I, Protti N, Luca Reversi, Bruschi P, Ferrari C, Cansolino L, Panza L, Ristori S, Altieri S. Boron concentration measurements by alpha spectrometry and quantitative neutron autoradiography in cells and tissues treated with different boronated formulations and administration protocols. Appl Radiat Isot 2014; 88:78-80. [DOI: 10.1016/j.apradiso.2013.12.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2012] [Revised: 11/28/2013] [Accepted: 12/03/2013] [Indexed: 10/25/2022]
|
30
|
Abstract
The compound class of 3-carboranyl thymidine analogues (3CTAs) are boron delivery agents for boron neutron capture therapy (BNCT), a binary treatment modality for cancer. Presumably, these compounds accumulate selectively in tumor cells via intracellular trapping, which is mediated by hTK1. Favorable in vivo biodistribution profiles of 3CTAs led to promising results in preclinical BNCT of rats with intracerebral brain tumors. This review presents an overview on the design, synthesis, and biological evaluation of first- and second-generation 3CTAs. Boronated nucleosides developed prior to 3CTAs for BNCT and non-boronated N3-substituted thymidine conjugates for other areas of cancer therapy and imaging are also described. In addition, basic features of carborane clusters, which are used as boron moieties in the design and synthesis of 3CTAs, and the biological and structural features of TK1-like enzymes, which are the molecular targets of 3CTAs, are discussed.
Collapse
|
31
|
Carboranyl-porphyrazines and derivatives for boron neutron capture therapy: From synthesis to in vitro tests. Coord Chem Rev 2013. [DOI: 10.1016/j.ccr.2013.03.035] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
32
|
Waller RC, Booth RE, Feakes DA. Evaluation of the binding of polyhedral borane anions to representative proteins. J Inorg Biochem 2013; 124:11-4. [DOI: 10.1016/j.jinorgbio.2013.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Revised: 03/13/2013] [Accepted: 03/13/2013] [Indexed: 11/15/2022]
|
33
|
Short and long-term exposure of CNS cell lines to BPA-f a radiosensitizer for Boron Neutron Capture Therapy: safety dose evaluation by a battery of cytotoxicity tests. Neurotoxicology 2013; 35:84-90. [DOI: 10.1016/j.neuro.2012.12.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2012] [Revised: 12/13/2012] [Accepted: 12/14/2012] [Indexed: 12/21/2022]
|
34
|
Abstract
INTRODUCTION Boron lies on the borderline between metals and non-metals in the periodic table. As such, it possesses peculiarities which render it suitable for a variety of applications in chemistry, technology and medicine. However, boron's peculiarities have been exploited only partially so far. AREAS COVERED In this review, the authors highlight selected areas of research which have witnessed new uses of boron compounds in recent times. The examples reported illustrate how difficulties in the synthesis and physicochemical characterization of boronated molecules, encountered in past years, can be overcome with positive effects in different fields. EXPERT OPINION Many potentialities of boron-based systems reside in the peculiar properties of both boron atoms (the ability to replace carbon atoms, electron deficiency) and of boronated compounds (hydrophobicity, lipophilicity, versatile stereochemistry). Taken in conjunction, these properties can provide innovative drugs. The authors highlight the need to further investigate the assembly of boronated compounds, in terms of drug design, since the mechanisms required to obtain supramolecular structures may be unconventional compared with the more standard molecules used. Furthermore, the authors propose that computational methods are a valuable tool for assessing the role of multicenter, quasi-aromatic bonds and its peculiar geometries.
Collapse
Affiliation(s)
- Laura Ciani
- University of Florence, Department of Chemistry & CSGI, Sesto Fiorentino, Italy.
| | | |
Collapse
|
35
|
Barth RF, Vicente MGH, Harling OK, Kiger WS, Riley KJ, Binns PJ, Wagner FM, Suzuki M, Aihara T, Kato I, Kawabata S. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 2012; 7:146. [PMID: 22929110 PMCID: PMC3583064 DOI: 10.1186/1748-717x-7-146] [Citation(s) in RCA: 291] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2012] [Accepted: 07/23/2012] [Indexed: 11/25/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Clinical interest in BNCT has focused primarily on the treatment of high grade gliomas, recurrent cancers of the head and neck region and either primary or metastatic melanoma. Neutron sources for BNCT currently have been limited to specially modified nuclear reactors, which are or until the recent Japanese natural disaster, were available in Japan, the United States, Finland and several other European countries, Argentina and Taiwan. Accelerators producing epithermal neutron beams also could be used for BNCT and these are being developed in several countries. It is anticipated that the first Japanese accelerator will be available for therapeutic use in 2013. The major hurdle for the design and synthesis of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations in the range of 20 μg/g. This would be sufficient to deliver therapeutic doses of radiation with minimal normal tissue toxicity. Two boron drugs have been used clinically, a dihydroxyboryl derivative of phenylalanine, referred to as boronophenylalanine or “BPA”, and sodium borocaptate or “BSH” (Na2B12H11SH). In this report we will provide an overview of other boron delivery agents that currently are under evaluation, neutron sources in use or under development for BNCT, clinical dosimetry, treatment planning, and finally a summary of previous and on-going clinical studies for high grade gliomas and recurrent tumors of the head and neck region. Promising results have been obtained with both groups of patients but these outcomes must be more rigorously evaluated in larger, possibly randomized clinical trials. Finally, we will summarize the critical issues that must be addressed if BNCT is to become a more widely established clinical modality for the treatment of those malignancies for which there currently are no good treatment options.
Collapse
Affiliation(s)
- Rolf F Barth
- Department of Pathology, The Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH, 43210, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Heber EM, Kueffer PJ, Lee MW, Hawthorne MF, Garabalino MA, Molinari AJ, Nigg DW, Bauer W, Hughes AM, Pozzi ECC, Trivillin VA, Schwint AE. Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2012; 51:195-204. [PMID: 22271404 DOI: 10.1007/s00411-011-0399-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2011] [Accepted: 12/27/2011] [Indexed: 05/31/2023]
Abstract
Boron neutron capture therapy (BNCT) combines selective accumulation of (10)B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K[nido-7-CH(3)(CH(2))(15)-7,8-C(2)B(9)H(11)] in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K[nido-7-CH(3)(CH(2))(15)-7,8-C(2)B(9)H(11)] in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na(3) [ae-B(20)H(17)NH(3)], administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 ± 16.1 ppm at 48 h and to 43.9 ± 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.
Collapse
Affiliation(s)
- Elisa M Heber
- Department of Radiobiology, National Atomic Energy Commission, San Martin, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Pietrangeli D, Ristori S, Rosa A, Ricciardi G. Carboranylporphyrazines for anti-cancer therapies: synthesis and physicochemical properties. J PORPHYR PHTHALOCYA 2012. [DOI: 10.1142/s1088424610002574] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The synthesis, the salient physicochemical properties, and liposome insertion of carboranyl-alkylthio-porphyrazines, a new family of potential BNCT agents, are here reviewed together with recent progresses in their metalation and conversion in the water-soluble counterparts.
Collapse
Affiliation(s)
- Daniela Pietrangeli
- Dipartimento di Chimica, Università della Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy
| | - Sandra Ristori
- Dipartimento di Chimica, Università di Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino (Fi), Italy
- CSGI, Università di Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino (Fi), Italy
| | - Angela Rosa
- Dipartimento di Chimica, Università della Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy
| | - Giampaolo Ricciardi
- Dipartimento di Chimica, Università della Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy
| |
Collapse
|
38
|
Lai CH, Lin YC, Chou FI, Liang CF, Lin EW, Chuang YJ, Lin CC. Design of multivalent galactosyl carborane as a targeting specific agent for potential application to boron neutron capture therapy. Chem Commun (Camb) 2012; 48:612-4. [DOI: 10.1039/c1cc14447b] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
39
|
Fluorinated porphyrinoids and their biomedical applications. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY C-PHOTOCHEMISTRY REVIEWS 2011. [DOI: 10.1016/j.jphotochemrev.2011.09.005] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
40
|
Fujii S, Masuno H, Taoda Y, Kano A, Wongmayura A, Nakabayashi M, Ito N, Shimizu M, Kawachi E, Hirano T, Endo Y, Tanatani A, Kagechika H. Boron Cluster-based Development of Potent Nonsecosteroidal Vitamin D Receptor Ligands: Direct Observation of Hydrophobic Interaction between Protein Surface and Carborane. J Am Chem Soc 2011; 133:20933-41. [DOI: 10.1021/ja208797n] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | | | - Yoshiyuki Taoda
- Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | | | - Angsuma Wongmayura
- Department of Chemistry, Faculty of Science, Ochanomizu University, 2-1-1 Otsuka, Bunkyo-ku, Tokyo 112-8610, Japan
| | | | | | | | | | | | - Yasuyuki Endo
- Faculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan
| | - Aya Tanatani
- Department of Chemistry, Faculty of Science, Ochanomizu University, 2-1-1 Otsuka, Bunkyo-ku, Tokyo 112-8610, Japan
| | | |
Collapse
|
41
|
Calabrese G, Nesnas JJ, Barbu E, Fatouros D, Tsibouklis J. The formulation of polyhedral boranes for the boron neutron capture therapy of cancer. Drug Discov Today 2011; 17:153-9. [PMID: 21978988 DOI: 10.1016/j.drudis.2011.09.014] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Revised: 09/14/2011] [Accepted: 09/23/2011] [Indexed: 11/28/2022]
Abstract
The early promise of boron neutron capture therapy as a method for the treatment of cancer has been inhibited by the inherent toxicity associated with therapeutically useful doses of ¹⁰B-containing pharmacophores, the need for target-tissue specificity and the challenges imposed by biological barriers. Although developments in the synthetic chemistry of polyhedral boranes have addressed issues of toxicity to a considerable extent, the optimisation of the transport and the delivery of boronated agents to the site of action--the subject of this review--is a challenge that is addressed by the development of innovative formulation strategies.
Collapse
Affiliation(s)
- Gianpiero Calabrese
- School of Pharmacy and Chemistry, Kingston University, Kingston-upon Thames KT1 2EE, UK.
| | | | | | | | | |
Collapse
|
42
|
Geninatti-Crich S, Alberti D, Szabo I, Deagostino A, Toppino A, Barge A, Ballarini F, Bortolussi S, Bruschi P, Protti N, Stella S, Altieri S, Venturello P, Aime S. MRI-guided neutron capture therapy by use of a dual gadolinium/boron agent targeted at tumour cells through upregulated low-density lipoprotein transporters. Chemistry 2011; 17:8479-86. [PMID: 21671294 DOI: 10.1002/chem.201003741] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2010] [Indexed: 01/05/2023]
Abstract
The upregulation of low-density lipoprotein (LDL) transporters in tumour cells has been exploited to deliver a sufficient amount of gadolinium/boron/ligand (Gd/B/L) probes for neutron capture therapy, a binary chemio-radiotherapy for cancer treatment. The Gd/B/L probe consists of a carborane unit (ten B atoms) bearing an aliphatic chain on one side (to bind LDL particles), and a Gd(III)/1,4,7,10-tetraazacyclododecane monoamide complex on the other (for detection by magnetic resonance imaging (MRI)). Up to 190 Gd/B/L probes were loaded per LDL particle. The uptake from tumour cells was initially assessed on cell cultures of human hepatoma (HepG2), murine melanoma (B16), and human glioblastoma (U87). The MRI assessment of the amount of Gd/B/L taken up by tumour cells was validated by inductively coupled plasma-mass-spectrometric measurements of the Gd and B content. Measurements were undertaken in vivo on mice bearing tumours in which B16 tumour cells were inoculated at the base of the neck. From the acquisition of magnetic resonance images, it was established that after 4-6 hours from the administration of the Gd/B/L-LDL particles (0.1 and 1 mmol kg(-1) of Gd and (10)B, respectively) the amount of boron taken up in the tumour region is above the threshold required for successful NCT treatment. After neutron irradiation, tumour growth was followed for 20 days by MRI. The group of treated mice showed markedly lower tumour growth with respect to the control group.
Collapse
Affiliation(s)
- Simonetta Geninatti-Crich
- Department of Chemistry IFM and Molecular Imaging Center, Università di Torino, Via Nizza 52, 10125 Torino, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Pietrangeli D, Rosa A, Pepe A, Ricciardi G. Symmetrically Substituted nido-Carboranylphthalocyanines: Facile Synthesis, Characterization, and Solution Properties. Evidence for Intra- and Intermolecular H+/K+ Exchange. Inorg Chem 2011; 50:4680-2. [DOI: 10.1021/ic200458k] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Daniela Pietrangeli
- Dipartimento di Chimica, Università della Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Angela Rosa
- Dipartimento di Chimica, Università della Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Antonietta Pepe
- Dipartimento di Chimica, Università della Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| | - Giampaolo Ricciardi
- Dipartimento di Chimica, Università della Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
| |
Collapse
|
44
|
Zhang L, Lin Y, Wang J, Yao W, Wu W, Jiang X. A Facile Strategy for Constructing Boron-Rich Polymer Nanoparticles via a Boronic Acid-Related Reaction. Macromol Rapid Commun 2011; 32:534-9. [DOI: 10.1002/marc.201000757] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2010] [Indexed: 11/10/2022]
|
45
|
Cappelli A, Valenti S, Mancini A, Giuliani G, Anzini M, Altieri S, Bortolussi S, Ferrari C, Clerici AM, Zonta C, Carraro F, Filippi I, Giorgi G, Donati A, Ristori S, Vomero S, Concas A, Biggio G. Carborane-Conjugated 2-Quinolinecarboxamide Ligands of the Translocator Protein for Boron Neutron Capture Therapy. Bioconjug Chem 2010; 21:2213-21. [DOI: 10.1021/bc100195s] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Andrea Cappelli
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Salvatore Valenti
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Alessandra Mancini
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Germano Giuliani
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Maurizio Anzini
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Saverio Altieri
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Silva Bortolussi
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Cinzia Ferrari
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Anna Maria Clerici
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Cecilia Zonta
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Fabio Carraro
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Irene Filippi
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Gianluca Giorgi
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Alessandro Donati
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Sandra Ristori
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Salvatore Vomero
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Alessandra Concas
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| | - Giovanni Biggio
- Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy, Dipartimento di Fisica Nucleare e Teorica, Università di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Pavia, Via Ugo Bassi 6, 27100 Pavia, Italy, Dipartimento di Scienze Chirurgiche, Laboratorio di Chirurgia Sperimentale, Università di Pavia, Via Ferrata 9, 27100 Pavia, Italy,
| |
Collapse
|
46
|
Kokado K, Nagai A, Chujo Y. Poly(γ-glutamic acid) Hydrogels with Water-Sensitive Luminescence Derived from Aggregation-Induced Emission of o-Carborane. Macromolecules 2010. [DOI: 10.1021/ma100792z] [Citation(s) in RCA: 88] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Kenta Kokado
- Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510, Japan
| | - Atsushi Nagai
- Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510, Japan
| | - Yoshiki Chujo
- Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510, Japan
| |
Collapse
|
47
|
|